More articles from Current Drug Therapy

  • Beta-blockers for hypertension: Are they going out of style?
    Qi Che, MD, PhD, Martin J. Schreiber, MD and Mohammed A. Rafey, MD, MS
    Cleveland Clinic Journal of Medicine September 2009, 76 (9) 533-542; DOI: https://doi.org/10.3949/ccjm.76a.09030

    The outcomes of clinical trials have been disappointing, and the value of beta-blockers in treating hypertensive patients who do not have compelling indications for them has been questioned.

  • Pregabalin for fibromyalgia: Some relief but no cure
    Lauren Kim, MD, Sarah Lipton, MD and Atul Deodhar, MD
    Cleveland Clinic Journal of Medicine April 2009, 76 (4) 255-261; DOI: https://doi.org/10.3949/ccjm.76a.08024

    How will pregabalin (Lyrica) fit into the treatment of this challenging disease?

  • Perioperative statins: More than lipid-lowering?
    Leonard S. Feldman, MD and Daniel J. Brotman, MD
    Cleveland Clinic Journal of Medicine September 2008, 75 (9) 654-662;

    Soon, the checklist for internists seeing patients about to undergo surgery may include prescribing one of the lipid-lowering drugs called statins.

  • Anemia of chronic kidney disease: When normalcy becomes undesirable
    Sevag G. Demirjian, MD and Saul Nurko, MD
    Cleveland Clinic Journal of Medicine May 2008, 75 (5) 353-356;

    Several recent studies indicate that raising hemoglobin levels to the normal range with erythropoiesis-stimulating agents can be too much of a good thing, and the US Food and Drug Administration has issued a warning on the use of these drugs in renal disease.

  • What role will ‘gliptins’ play in glycemic control?
    Zachary Bloomgarden, MD and Andrew Drexler, MD
    Cleveland Clinic Journal of Medicine April 2008, 75 (4) 305-310;

    Sitagliptin (Januvia) is now available, vildagliptin (Galvus) is awaiting approval, and other “gliptins” are under development. Their greatest appeal appears to be their ability to stimulate insulin production with little risk of hypoglyecmia.

  • Treating pulmonary arterial hypertension: Cautious hope in a deadly disease
    Treating pulmonary arterial hypertension: Cautious hope in a deadly disease
    Omar A. Minai, MD and Marie M. Budev, DO, MPH
    Cleveland Clinic Journal of Medicine November 2007, 74 (11) 789-806;

    Advances have brought cautious hope for patients with this progressive and deadly disease. Intravenous prostanoids are still the most effective drugs for long-term treatment, but oral options are available for some patients who can be closely monitored.

  • Modafinil in the treatment of excessive daytime sleepiness
    Roxanne M. Valentino, MD and Nancy Foldvary-Schaefer, DO
    Cleveland Clinic Journal of Medicine August 2007, 74 (8) 561-571;

    We review the pharmacology, current approved and off-label uses, and side effects of this commonly prescribed wakefulness-promoting agent.

  • Atypical antipsychotics: New drugs, new challenges
    Manu Mathews, MD and David J. Muzina, MD
    Cleveland Clinic Journal of Medicine August 2007, 74 (8) 597-606;

    Second-generation antipsychotic, or atypical, drugs are much less likely than typical antipsychotics to cause movement disorders, but they come with a new variety of side effects, particularly metabolic ones.

  • Buprenorphine maintenance: A new treatment for opioid dependence
    Gregory B. Collins, MD and Mark S. Mcallister, MD
    Cleveland Clinic Journal of Medicine July 2007, 74 (7) 514-520;

    New regulations allow physicians who are certified in buprenorphine therapy to offer it in their offices, substantially increasing patient access to treatment for opioid dependence.

  • Newer hormonal therapies: Lower doses; oral, transdermal, and vaginal formulations
    Mala S. Sivanandy, MD, Nziavake Masimasi, MD and Holly L. Thacker, MD
    Cleveland Clinic Journal of Medicine May 2007, 74 (5) 369-375;

    We review some of the hormonal regimens that have been approved in the past 5 years.

Pages